Pradaxa capsules 110mg №60

Packaging

Indications and usage

Prevention of venous thromboembolism in patients after orthopedic surgery.

Contraindications

Known hypersensitivity to dabigatran or dabigatran etexilate or to one of the excipients.
Patients with severe renal insufficiency (creatinine clearance less than 30 ml / min).
Hemorrhagic disorders, patients with hemorrhagic diathesis, patients with spontaneous or pharmacologically induced impaired hemostasis.
Active clinically significant bleeding.
Liver dysfunction and liver disease that may affect survival.
Simultaneous intake of quinidine.
Organ damage as a result of clinically significant bleeding, including hemorrhagic stroke during the previous 6 months before the start of therapy.
Patients are less than 18 years old.

Dosage and administration

Inside While eating or on an empty stomach, drinking water.
Special instructions for the removal of capsules from the blister

Remove the capsules from the blister by peeling off the foil. Do not squeeze the capsules through the foil. Remove the foil so that it is convenient to remove the capsules.

Adults
Prevention of venous thromboembolism (BT) in patients after orthopedic surgery

The recommended dose is 220 mg once daily (2 capsules, 110 mg each).

Store in a dry place, at a temperature not higher than 25º С